Overview of Dr. Ingham
Dr. Matthew Ingham is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from UMass Chan Medical School and has been in practice 7 years. He is one of 378 doctors at New York-Presbyterian Hospital and one of 116 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 20 publications and over 500 citings.
Office
161 Fort Washington Ave
New York, NY 10032Fax+1 212-305-6861
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2010 - 2013
University of Massachusetts Medical SchoolClass of 2010
Certifications & Licensure
NY State Medical License 2013 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 75 citationsDissecting the treatment-naive ecosystem of human melanoma brain metastasis.Jana Biermann, Johannes C Melms, Amit Dipak Amin, Yiping Wang, Lindsay A Caprio
Cell. 2022-07-07 - 28 citationsMultiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer.Kazuya Masuda, Adam Kornberg, Jonathan Miller, Sijie Lin, Nathan Suek
JCI Insight. 2022-04-08 - 113 citationsPhase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced/Metastatic Solid Tumors or Lymphomas.Funda Meric-Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka
Clinical Cancer Research. 2021-10-29
Press Mentions
Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Three Presentations at Key Upcoming Clinical Oncology Conferences in NovemberNovember 1st, 2022- Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingNovember 13th, 2021
- Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid TumorsJune 2nd, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
